---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-006721"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:20:30.613909+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunocore reports Q4 2025 KIMMTRAK sales of $104.5M, FY $400M; TEBE-AM data 2H 2026

## Summary
- Q4 2025 KIMMTRAK net sales $104.5M (+24% YoY); FY2025 $400.0M (+29% YoY).
- FY2025 net loss narrowed to $35.5M from $51.1M in 2024; cash $864.2M.
- R&D spend rose to $274.9M (FY2025) on autoimmune programs and Phase 3 trials.
- TEBE-AM Phase 3 enrollment complete 1H 2026; topline OS data expected 2H 2026.
- PRAME and HIV clinical data presentations expected 2H 2026.

## SEC filing metadata
- accession: 0001140361-26-006721
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036126006721/0001140361-26-006721-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036126006721/ef20066378_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-006721
- JSON: https://secwatch.observer/filing/0001140361-26-006721.json
- Plain text: https://secwatch.observer/filing/0001140361-26-006721.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.